Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;193(2):253-264.
doi: 10.1007/s10549-022-06572-w. Epub 2022 Mar 26.

Invasive lobular carcinoma: an understudied emergent subtype of breast cancer

Jason A Mouabbi  1 , Amy Hassan  2 , Bora Lim  3 , Gabriel N Hortobagyi  4 , Debasish Tripathy  4 , Rachel M Layman  4
Affiliations
Review

Invasive lobular carcinoma: an understudied emergent subtype of breast cancer

Jason A Mouabbi et al. Breast Cancer Res Treat. 2022 Jun.

Abstract

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer after invasive ductal carcinoma (IDC), accounting for 10-15% of all breast cancer cases. Although most ILCs are of the luminal A intrinsic subtype, with favorable prognostic features, conflicting literature data are available on their outcomes compared to IDC with reports suggesting a higher risk of distant recurrence after 10 years. Historically, studies have combined ILC and IDC, with outcomes largely driven by the behavior of IDC given that it represents 90% of breast cancers. However, over the past 5 years, reports of several studies aimed at understanding ILC at the clinical, cellular, and molecular levels have been published, showing that IDC and ILC are distinct entities. In this review, we highlight the unique characteristics of ILC and describe the need for dedicated ILC clinical trials.

Keywords: CDH1; ER+; Endocrine therapy; Estrogen receptor positive; HR+; ILC; Invasive lobular carcinoma; Review article.

PubMed Disclaimer

References

    1. Li CI et al (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289(11):1421–1424 - PubMed - DOI
    1. Iorfida M et al (2012) Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 133(2):713–723 - PubMed - DOI
    1. Barroso-Sousa R, Metzger-Filho O (2016) Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Ther Adv Med Oncol 8(4):261–266 - PubMed - PMC - DOI
    1. Guiu S et al (2014) Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions? Crit Rev Oncol Hematol 92(3):235–257 - PubMed - DOI
    1. Pestalozzi BC et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26(18):3006–3014 - PubMed - DOI

LinkOut - more resources